Nanobiotix S a (NBTX) Quarterly Income Statement

Quarterly · GAAP · USD millions
Access NBTX Annual Income Statement →
Quarterly income statement trends provide context on Nanobiotix S a's margins, operating leverage, and earnings trajectory.
Quarterly Report, GAAP in USD millions
ITEM
(Dec 31 2025)
Q4 2025
0 0 0 (Dec 31 2024)
Revenues
Revenue From Contracts With Customers33.20
Total Revenue36.50
Costs & Expenses
Gross Profit36.50
Selling, Administration, Marketing22.80
Research and Development Expense25.89
OtherOperating Income Expense-0.07
Total operating costs including COS48.62
Operating income / -loss-12.12
Net Interest (-)Expense / Income0.00
Other loss / -income14.72
Total costs & expenses63.34
Income & Taxes
Income / -loss before income taxes-26.84
Income taxes expenses / -benefit0.00
Income after income taxes-26.84
Income / -loss from continuing operations-26.84
Net income / -loss-26.84
Income / -loss to shareholder-26.84
EBIT-26.84
EBITD-26.84
EBITDA-26.84
Earnings Per Share
Basic EPS (excl. extra items)0.00
Basic Net EPS0.00
Diluted Net EPS0.00
4 historic quarters locked

Sign in to unlock the full Nanobiotix S a income statement history.

About NBTX Quarterly Income Statement

What this statement shows

This page presents issuer-reported income statement data, detailing revenue, operating costs, expenses, and earnings as disclosed in SEC 10-Q filings and standardized by CSIMarket. The income statement reflects operating performance over a reporting period rather than financial position at a single date.

Revenue and expense treatment

Revenue and expense items are aligned to support period-to-period comparability. Operating and non-operating items, interest, and income taxes are classified based on issuer disclosures and XBRL tagging.

Source & verification

  • Source: SEC 10-Q filings
  • Filed with the SEC: n/a

Income statement figures represent operating results for each reporting period and may be revised in subsequent filings.